Pheochromocytoma-paraganglioma
MONDO:0035540A rare neuroendocrine tumor arising from chromaffin cells of the adrenal medulla (pheochromocytoma) or from sympathetic and parasympathetic ganglia (paraganglioma). These tumors are most often benign and may produce catecholamines in excess causing hypertension and sometimes severe acute cardiovascular complications.
1457 clinical trials for this condition and its sub-types, 18 tagged with Pheochromocytoma-paraganglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a new drug shrink Hard-to-Treat adrenal tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare c…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a daily pill tame rare cancers in teens? new trial investigates
Disease control Not yet recruitingThis phase 2 trial tests the safety of belzutifan, a daily oral tablet, in adolescents with rare solid tumors that cannot be surgically removed or have spread. The study includes three tumor types: pheochromocytoma/paraganglioma (PPGL), wild-type gastrointestinal stromal tumors (…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Italian study examines targeted radiation for rare gland tumors
Disease control Not yet recruitingThis study looks back at how well a type of targeted radiation therapy (PRRT) works for people with advanced pheochromocytoma and paraganglioma, rare tumors of the adrenal glands. Researchers will analyze data from about 210 patients treated in Italy over 24 years. The goal is to…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New imaging agent could improve detection of rare cancers
Diagnosis Not yet recruitingThis study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers a…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC